All In Biotech

Drug Trial Radar · NCT06897748

A Study to Investigate Efficacy and Safety of Tozorakimab Injections Compared With Placebo in Adult Participants With Symptomatic Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations and Elevated Eosinophils

A Phase II, Multicentre, Randomised, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab in Participants With Symptomatic Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations and Elevated Eosinophils (COMETA)

Last checked: Nov 20, 2026Latest source record: Jul 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

98

Actual

Start

Apr 12, 2025

Primary completion

Apr 21, 2026

Study completion Apr 21, 2026

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Mar 27, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to investigate lung function parameters, composite endpoint for exacerbations in chronic obstructive pulmonary disease (COPDCompEx), symptoms and to provide safety information after tozorakimab or placebo administrations in participants with symptomatic chronic obstructive pulmonary disease (COPD) with history of exacerbations and high blood eosinophil counts. Study details include the following: * The maximum duration of the screening/run-in period is 5 weeks. An additional unscheduled visit may be performed prior to randomization to repeat safety assessments as deemed necessary by the investigator. * Eligible patients will enter 12-week treatment (intervention) period with site visits and investigational product (IP) administration every 2 weeks. * Participants who complete a treatment period, and have not been prematurely discontinued from IP, will enter a 10-week post-intervention follow-up period. * The study duration will be 27 weeks at maximum for each participant.

Conditions

  • Chronic Obstructive Pulmonary Disease (COPD)

Interventions

  • PlaceboDrug

    Placebo administered subcutaneously, equivalent volume to tozorakimab throughout the study

  • TozorakimabDrug

    Administered subcutaneously tozorakimab and placebo throughout the study

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline to Week 12 in Pre-bronchodilator Forced Expiratory Volume in 1 Second (Pre-BD FEV1) as Measured in ClinicTime frame: Baseline through Week 12

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Aramil, Russia

  • Research Site

    Izhevsk, Russia

  • Research Site

    Moscow, Russia

  • Research Site

    Moscow, Russia

  • Research Site

    Moscow, Russia

  • Research Site

    Moscow, Russia

  • Research Site

    Omsk, Russia

  • Research Site

    Penza, Russia

  • Research Site

    Perm, Russia

  • Research Site

    Saint Petersburg, Russia

  • Research Site

    Saratov, Russia

  • Research Site

    Ulyanovsk, Russia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.